Douglas Love Sells 5,021 Shares of Annexon, Inc. (NASDAQ:ANNX) Stock

Annexon, Inc. (NASDAQ:ANNX) CEO Douglas Love sold 5,021 shares of Annexon stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $2.95, for a total transaction of $14,811.95. Following the completion of the sale, the chief executive officer now directly owns 351,554 shares in the company, valued at $1,037,084.30. This represents a 1.41 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Annexon Trading Down 12.1 %

ANNX stock traded down $0.37 during midday trading on Tuesday, reaching $2.70. The stock had a trading volume of 1,478,333 shares, compared to its average volume of 1,413,788. The company’s fifty day simple moving average is $4.41 and its 200 day simple moving average is $5.63. The company has a market cap of $287.79 million, a price-to-earnings ratio of -2.57 and a beta of 1.07. Annexon, Inc. has a 52-week low of $2.70 and a 52-week high of $8.40.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of ANNX. State Street Corp raised its holdings in shares of Annexon by 116.6% during the 3rd quarter. State Street Corp now owns 3,841,879 shares of the company’s stock worth $22,744,000 after acquiring an additional 2,068,294 shares during the period. Sio Capital Management LLC purchased a new position in shares of Annexon during the 3rd quarter worth $8,484,000. Sphera Funds Management LTD. purchased a new position in shares of Annexon during the 4th quarter worth $6,377,000. Ameriprise Financial Inc. raised its holdings in shares of Annexon by 483.6% during the 4th quarter. Ameriprise Financial Inc. now owns 926,642 shares of the company’s stock worth $4,754,000 after acquiring an additional 767,869 shares during the period. Finally, TFG Asset Management GP Ltd raised its holdings in shares of Annexon by 78.5% during the 4th quarter. TFG Asset Management GP Ltd now owns 1,400,000 shares of the company’s stock worth $7,182,000 after acquiring an additional 615,645 shares during the period.

Analyst Ratings Changes

ANNX has been the topic of a number of research analyst reports. HC Wainwright reissued a “buy” rating and issued a $30.00 price target on shares of Annexon in a research note on Tuesday, December 17th. Cantor Fitzgerald restated an “overweight” rating on shares of Annexon in a report on Friday, November 15th. Finally, Needham & Company LLC restated a “buy” rating and issued a $16.00 price objective on shares of Annexon in a report on Friday, November 15th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $15.80.

About Annexon

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.